Eaton Vance Worldwide Health Sciences Fund Class C (ECHSX)
Fund Assets | 1.02B |
Expense Ratio | 1.92% |
Min. Investment | $1,000 |
Turnover | n/a |
Dividend (ttm) | 0.60 |
Dividend Yield | 4.72% |
Dividend Growth | 94.57% |
Payout Frequency | Annual |
Ex-Dividend Date | Dec 5, 2024 |
Previous Close | 12.61 |
YTD Return | -2.24% |
1-Year Return | -6.14% |
5-Year Return | 25.81% |
52-Week Low | 12.15 |
52-Week High | 15.70 |
Beta (5Y) | n/a |
Holdings | 49 |
Inception Date | Jan 5, 1998 |
About ECHSX
The Fund's investment strategy focuses on GL Health/Biotech with 1.97% total expense ratio. The minimum amount to invest in Eaton Vance Growth Trust: Eaton Vance Worldwide Health Sciences Fund; Class C Shares is $1,000 on a standard taxable account. Eaton Vance Growth Trust: Eaton Vance Worldwide Health Sciences Fund; Class C Shares seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. ECHSX normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care.
Performance
ECHSX had a total return of -6.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.87%.
Top 10 Holdings
52.10% of assetsName | Symbol | Weight |
---|---|---|
Eli Lilly and Company | LLY | 10.52% |
AbbVie Inc. | ABBV | 6.71% |
AstraZeneca PLC | AZN | 5.03% |
UnitedHealth Group Incorporated | UNH | 4.89% |
Roche Holding AG | ROG | 4.80% |
Abbott Laboratories | ABT | 4.58% |
Bristol-Myers Squibb Company | BMY | 4.24% |
Novo Nordisk A/S | NOVO.B | 4.15% |
Johnson & Johnson | JNJ | 3.64% |
Thermo Fisher Scientific Inc. | TMO | 3.55% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 5, 2024 | $0.5987 | Dec 6, 2024 |
Dec 7, 2023 | $0.3077 | Dec 8, 2023 |
Dec 8, 2022 | $0.5351 | Dec 9, 2022 |
Dec 9, 2021 | $1.086 | Dec 10, 2021 |
Dec 10, 2020 | $0.8312 | Dec 11, 2020 |
Dec 3, 2019 | $0.5422 | Dec 4, 2019 |